Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  busulfan
Find trials that include:  Any drugs shown
Results 1-25 of 60 for your search:
Start Over
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Melphalan with or without Busulfan before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: 2010-0071, NCI-2011-02760, cs2010-0032635MA, NCT01413178
Busulfan, Fludarabine Phosphate, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: HEM-05011-L, NCI-2013-00779, CDR0000447204, OHSU-210, OHSU-HEM-05011-L, NCT00245037
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
Carfilzomib in Preventing Relapse and Graft-versus-Host Disease in Patients with High-Risk Hematologic Malignancies Undergoing Donor Hematopoietic Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18 to less than 65
Trial IDs: UMCC 2014.010, NCI-2014-01923, 2014.010, CR00046767, HUM00084170, NCT02145403
Busulfan, Cyclophosphamide, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Juvenile Myelomonocytic Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: MT1999-20, NCI-2010-01703, 1999LS073, NCT00167219
Busulfan, Melphalan, and Fludarabine Phosphate Followed By Donor Umbilical Cord Blood Transplant in Treating Infants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Age: 2 and under at diagnosis
Trial IDs: MT2005-25, NCI-2010-02159, 2005LS075, UMN-2005LS075, UMN-MT2005-25, UMN-0511M77206, NCT00357565
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients with High Risk Malignancies
Phase: Phase II
Type: Treatment
Age: Under 60
Trial IDs: 2008-0363, NCI-2012-01630, NCT00857389
Busulfan and Clofarabine Followed by Donor Stem Cell Transplant in Treating Patients with Acute Leukemia or Lymphoma in Remission or Relapse
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 65
Trial IDs: 2009-0209, NCI-2012-01270, NCI-2009-01649, NCT00990249
Allogeneic Transplant in HIV Patients (BMT CTN 0903)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 and over
Trial IDs: BMTCTN0903, NCI-2014-00311, 710, U01HL069294, NCT01410344
Busulfan and Fludarabine Phosphate in Treating Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2011-0958, NCI-2012-00573, NCT01572662
Clofarabine, Busulfan and Fludarabine Phosphate Followed by Donor Stem Cell Transplant in Treating Young Patients With High Risk Hematological Malignancies or Hematological Disorders
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 months to 30 years
Trial IDs: CC #110819, NCI-2012-00800, NCT01596699
Vaccine Therapy After Donor Stem Cell Transplant in Treating Patients With Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-217, NCI-2013-00286, NCT01773395
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate before Donor Hematopoietic Cell Transplant in Treating Younger Patients with Juvenile Myelomonocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 18
Trial IDs: ASCT1221, NCI-2013-00738, COG-ASCT1221, NCT01824693
Donor Stem Cell Transplant in Treating Patients with GATA2 Mutations
Phase: Phase II
Type: Treatment
Age: 6 to 70
Trial IDs: 13-C-0132, NCI-2013-01561, 130132, P131226, NCT01861106
Start Over